Steven Girgenti, Executive Chairman of the Board, founded and ran several successful businesses, including DermWorx Incorporated, a specialty pharmaceutical company dedicated to solutions for dermatological conditions. Mr. Girgenti was also the founder and CEO of Healthworld, a leading global healthcare marketing services and communications network with over $1 billion in billing and 55 offices in 36 countries.  The network has more than 1,000 brand assignments from nearly 200 clients worldwide, providing strategic marketing and communications services to many of the world’s leading healthcare companies.  Under his leadership, the company made numerous acquisitions to expand and diversify the business.  Founded in 1986, Healthworld went public in 1997.  In 1998, and again in 1999, Business Week named Healthworld one of the Best Small Corporations in America.  In 1999, Forbes listed Healthworld as one of the 200 Best Small Companies.  Healthworld is now owned by WPP, the largest media and communications firm in the world.  Mr. Girgenti was recognized as “Entrepreneur of the Year” by NASDAQ in 1999, and was named Med Ad News’ first “Medical Advertising Man of the Year” in 2000.  Mr. Girgenti serves as a Director of Vycor Medical and is the Vice Chairman of the Board of Governors for the Mount Sinai Hospital Prostate Disease and Research Center in New York City. He is also on the Board of Directors for Jack Martin Fund, a Mount Sinai Hospital-affiliated charitable organization devoted to pediatric oncology research.  Mr. Girgenti sits on the Advisory Board of Vatera Capital, an investment banking firm founded by Michael Jaharis.  In 2010 he was inducted into the Medical Advertising Hall of Fame.  He graduated from Columbia University and has worked in the pharmaceutical industry since 1968 for companies such as Bristol-Myers Squibb, Carter Wallace and DuPont, as well as marketing services and advertising agencies that specialize in healthcare. During his career, Steve has held positions in Marketing Research, Product Management, New Product Planning and Commercial Development.

Maria Zannes, Chief Executive Officer, President, and Director, brings more than 30 years of executive-level management experience dedicated to defining and advancing company goals and overcoming obstacles impeding corporate success.  In her current capacity, she is building a team of award-winning scientists and executives who are advancing the Company’s biomedical technology and its business.   She was instrumental in securing public funding for research into lung cancer, including state support for a clinical trial of an early lung cancer test with the potential to significantly change the manner in which the disease is diagnosed and treated.   Her experience on Capitol Hill and as a lobbyist in more than a dozen state legislatures, including her prior positions as President of the Energy Recovery Council, the national trade group for a $10 billion industry, and as a legislative aide specializing in energy policy and law for Congressman Charles Wilson (D-TX), provides Ms. Zannes with an appreciation of how government can assist industry to advance new technologies for commercial success. She was General Manager of ECOS Corporation, a subsidiary of Burlington Environmental, and also served as a project manager at Wheelabrator Technologies, Inc. where she led project teams that developed, negotiated and financed the company’s renewable energy generation facilities.  Ms. Zannes began her career as a journalist, working for Voice of America and the Associated Press. She is licensed to practice law in New Mexico and is a non-practicing member of the Washington State Bar.  She has been awarded the Lifetime Achievement Award by the American Society of Mechanical Engineers and Columbia University’s Earth Engineering Center Award.  She continues to serve as a research associate with Columbia University Earth Engineering Center and is the co-founder of two engineering research centers at the university.  Ms. Zannes received her B.A. in Journalism from the University of New Mexico and her J.D. from the University of Puget Sound in Washington State.

Robert A. Anderson, Director, has more than 40 years of broad experience including advanced strategic planning and product launches within the healthcare industry.  He advanced within several healthcare companies including CIBA, Becton Dickinson, Pfizer, Warner Lambert-Parke-Davis, Schering Plough and Centocor.  At Pfizer he was Product Manager for their antibiotic product line, one of the world’s largest at the time. At Warner-Lambert-Parke-Davis, Mr. Anderson controlled a multi-million dollar budget and advanced to Group Product Director, responsible for both in-line and pipeline products in a number of therapeutic areas.  In addition, he directed the marketing research function and was responsible for coordinating the marketing strategic plan.  Subsequently, Mr. Anderson became Vice-President of Marketing for the Key Pharmaceuticals division of Schering-Plough and following that was brought on board at Centocor, a world-wide healthcare company (now owned by J & J) to build the business infrastructure, including developing Centocor’s marketing plans and budget, U.S. pre-launch product strategies and license negotiations.  In 1992, Mr. Anderson joined Physicians World Communications Group (PWCG) as Vice-President.  He was later appointed to the Executive Committee, made a Partner and was appointed Chief Operating Officer of the Company in 1997.  During his tenure, PWCG grew to be the largest medical education company in the U.S., quadrupling its total sales to $150 million.  After the acquisition of PWCG by the Thomson Corp. in 2000, Mr. Anderson was appointed Chief Marketing Officer for the several Thomson medical education companies and stayed on for several years.  Mr. Anderson currently provides Executive Management services to a number of CEOs of healthcare companies. Mr. Anderson received a B.A. in political science from Rutgers University and is a member of MENSA.

Mr. Barry R. Frankel, Director, serves on the Board of Directors of several life science companies in addition to bioAffinity Technologies, including Cireca Theranostics, Nanocare Therapeutics, and Chimera Biotechnology.  He is the Managing Director, Life Sciences, at Huron Consulting Group where he provides creative and actionable strategic solutions to challenges faced by pharmaceutical, device/diagnostic, biotechnology, healthcare intermediary and investment firms. He founded Frankel Group LLC in March 1993 that later was sold to Huron Consulting Group in January 2014 and led Frankel Group’s expansion as a leading life science global strategy consulting firm and it’s entry into the venture capital arena, holding an asset management advisory role with Equity4life AG.  Mr. Frankel was President of SJ Weinstein Associates, an advertising and marketing strategy firm from 1982 to 1993, where he formulated marketing and communications strategies for some of the leading life science companies.  From 1977 to 1982, Mr. Frankel served in senior marketing and strategy positions at Pfizer Inc. His duties included strategic planning for Pfizer Pharmaceuticals, as well as senior marketing positions at Pfizer in the anti-infective, multisource pharmaceutical and diagnostic markets.  Prior to Pfizer, he worked at Citibank Investment Management Group from 1974 to 1977 as a Senior Life Science Research Analyst. He holds a Masters in Business Administration with Distinction from The Wharton School, University of Pennsylvania, and a Bachelors of Science Summa Cum Laude in Engineering from Rutgers University.   Mr. Frankel is author of the article, The Current State of the Pharmaceutical Industry Research & Development: Four Part Series.  Mr. Frankel serves as the Co-Chairman of the Wainscott New York Community Advisory Council and lives in New York City with his wife Karen and two grown children, Erin and Matt.

Mr. Myron Holubiak, Director, is President and Chief Executive Officer of Leonard-Meron Biosciences, Inc., a drug development company in the field of critical medicine.  Mr. Holubiak also is Chairman of the Board of BioScrip, Inc., a leading infusion services provider with nationwide pharmacy and home nursing capabilities, and serves on the Board of Directors for Assembly Biosciences, Inc., where he is also chair of the Compensation Committee.  Mr. Holubiak is a senior partner and Director of 1-800-DOCTORS, Inc.  Mr. Holubiak is the former President of Roche Laboratories, Inc., and has served on the Board of Directors of Nastech Pharmaceutical Company, Inc. (now Marina Biotech, Inc.).  Along with Mr. Emery Dupuis, Mr. Holubiak was the co-founder of Emron, Inc.  Mr. Holubiak holds a BS degree in biophysics and molecular biology from the University of Pittsburgh with graduate work in biophysics.  He completed advanced executive training at Tuck’s School of Business at Dartmouth College, the Harvard Business School, the University of London, and the Centre for Health Economics at the University of York.  He has lectured at the joint program for entrepreneurship at the University of Pittsburgh School of Pharmacy and the Katz Business School and has been guest lecturer at the Fordham University Graduate School of Business, Columbia School of Business, and the Leonard Davis Institute at The Wharton School, University of Pennsylvania.  Mr. Holubiak has been meeting leader and panel member at the Family Medicine Education Consortium.  He has been a consultant to Hewlett-Packard at their Master’s Driven Selling Workshop.  He also served as a member of the Advisory Board for the National Institute of Mental Health program: Depression, Awareness, Recognition, and Treatment (D/ART).